Breathtaking science

Developing innovative therapeutics to transform

the standard of care for respiratory diseases
Search for better science

We aim to build a strong clinical R&D pipeline to

target debilitating respiratory diseases
Our science

Targeting respiratory diseases with significant unmet medical needs.

There are millions of patients suffering globally from chronic, debilitating respiratory conditions that are not well treated by existing medicines. There is a real and pressing need for new treatments. We are focused on developing these treatments. Our efficient R&D outsourcing model gives us access to leading experts and organisations around the globe and our agility and focus on our core competencies provide the highest standards of pre-clinical and clinical development.

See our product pipeline

Our strategy

To progress projects with high commercial potential, whilst delivering both near-and long-term value to our shareholders.

We have a clear view of the medical need and commercial potential of our novel products in global, multi-billion dollar markets. Making the right decisions now, with partners and investors, will help us identify the quickest and most effective route to market allowing us to potentially transform the lives of patients suffering from these debilating diseases, with the returns enabling us to continue this mission into the future.

Find out more about us

Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative theraputics.

Latest press releases

27 June 2017

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory approval in five European countries, comprising the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic, for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD). The trial is expected to commence in the third quarter of 2017, with top-line data expected in the second ha…

22 June 2017

Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma…

Press releases

Regulatory news